MNG
TAK icon

Manning & Napier Group’s Takeda Pharmaceutical TAK Stock Holding History

Manning & Napier Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$3.77M Sell
271,786
-26,100
-9% -$380K 0.04% 196
2023
Q4 		$4.25M Sell
297,886
-4,381
-1% -$62.2K 0.05% 190
2023
Q3 		$4.68M Sell
302,267
-3,189
-1% -$49.4K 0.06% 188
2023
Q2 		$4.8M Buy
305,456
+22,939
+8% +$376K 0.05% 196
2023
Q1 		$4.66M Sell
282,517
-7,646
-3% -$122K 0.05% 218
2022
Q4 		$4.53M Sell
290,163
-5,543
-2% -$77.4K 0.06% 218
2022
Q3 		$3.83M Buy
295,706
+907
+0.3% +$12.6K 0.05% 232
2022
Q2 		$4.14M Buy
294,799
+3,397
+1% +$48.5K 0.05% 232
2022
Q1 		$4.17M Sell
291,402
-27,903
-9% -$410K 0.04% 237
2021
Q4 		$4.35M Sell
319,305
-2,717
-0.8% -$38.1K 0.04% 243
2021
Q3 		$5.27M Sell
322,022
-2,207
-0.7% -$37K 0.05% 226
2021
Q2 		$5.46M Buy
+324,229
New +$5.52M 0.04% 235

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Manning & Napier Group's TAK Position: Q1 2024 in Review

Manning & Napier Group reduced its Takeda Pharmaceutical (TAK) stake by 8.8% in Q1 2024, selling an estimated $380K and leaving 271,786 shares worth $3.77M. The position accounts for 0.04% of the portfolio, ranked #196.

Manning & Napier Group first reported a position in TAK in Q2 2021 and has held it in 12 quarters since. The position peaked at $5.46M in Q2 2021. 314 funds tracked by Wall St. Rank hold TAK as of Q1 2024.

  • Manning & Napier Group held 271,786 shares of Takeda Pharmaceutical worth $3.77M as of Q1 2024.
  • Manning & Napier Group sold 26,100 Takeda Pharmaceutical shares in Q1 2024, an estimated $380K.
  • Takeda Pharmaceutical made up 0.04% of Manning & Napier Group's portfolio in Q1 2024, its #196 holding.
  • Manning & Napier Group first reported a position in Takeda Pharmaceutical in Q2 2021 and has held it in 12 quarters since.
  • Manning & Napier Group's Takeda Pharmaceutical position peaked at $5.46M in Q2 2021.
  • 314 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2024.

Based on Manning & Napier Group's 13F filing for Q1 2024, filed 15 Apr 2024.